BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) General Counsel Vincent Paul Liptak purchased 2,200 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of $16.00 per share, with a total value of $35,200.00. Following the completion of the transaction, the general counsel owned 111,412 shares of the company’s stock, valued at $1,782,592. This represents a 2.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Vincent Paul Liptak also recently made the following trade(s):
- On Friday, August 7th, Vincent Paul Liptak purchased 2,500 shares of BlossomHill Therapeutics stock. The stock was bought at an average price of $15.80 per share, with a total value of $39,500.00.
BlossomHill Therapeutics Stock Down 0.1%
Shares of NASDAQ:BLSM opened at $15.99 on Tuesday. BlossomHill Therapeutics, Inc. has a 1 year low of $15.25 and a 1 year high of $17.25.
Further Reading
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
